6 results about "Ziprasidone" patented technology

Disclosed is a method of treating patients with microvascular angina by using a combination of zibotentan and dapagliflozin.

The invention relates to the technical field of pharmaceutical preparations, in particular to ziprasidone sustained-release granules, ziprasidone controlled-release tablets and a preparation method. The invention aims to solve the problem of incomplete filling during sustained-release particle tabletting. The first aspect of the invention is to provide a ziprasidone sustained-release particle, and in the ziprasidone sustained-release particle, the proportion of particles with the particle size greater than 250 [mu] m is less than 30% by weight. The second aspect of the invention is to provide a method for preparing the ziprasidone sustained-release granule. The third aspect is to provide a ziprasidone controlled release tablet comprising the ziprasidone sustained release particle. The fourth aspect is to provide a method for preparing the ziprasidone controlled release tablet.

The invention provides a detection method for ziprasidone synthesis intermediate 3-(1-piperazinyl)-1,2-benzisothiazole hydrochloride, belonging to the technical field of drug quality analysis and detection. The invention selects acetonitrile and triethylamine-containing aqueous solution in a certain proportion as mobile phases, performs programmed gradient elution in coordination, and improves separation degree and analytical sensitivity; a diode array detector is adopted, and the 2008-2022Shimadzu Corporation LabSolutions software / similar software carried by the diode array detector is used to confirm the relative quantification of main impurities in the main product 3-(1-piperazinyl)-1,2-benzisothiazole hydrochloride; and the method provided by the invention has short analysis time, simple analysis operation and good repeatability and adaptability.

A combination for use in the prevention, alleviation or treatment of schizophrenia, comprising (a) a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and (b) an atypical antipsychotic agent selected from the group consisting of asenapine, clozapine, iloperidone, olanzapine, lurasidone, paliperidone, quetiapine, risperidone and ziprasidone: wherein, R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy; and one of A1 and A2 is CH, and the other is N.

Provided is an aqueous formulation of ziprasidone, stored for up to six months at 40° C., suitable for intramuscular injection. In these embodiments, the aqueous formulation (a) provides greater than 98% purity of the ziprasidone and / or (b) has less than 0.5% of USP Related Compound C with respect to ziprasidone. Also provided is a method of administering ziprasidone to a patient, the method comprising administering the above formulation to the patient intramuscularly through a syringe.

The invention relates to a method for detecting related substances of a ziprasidone starting material. The starting material is 6-chloroindole-2-ketone; according to the detection method, high performance liquid chromatography is adopted, phenylsilane bonded silica gel or adamantyl bonded silica gel is used as a chromatographic column of a filler, mobile phases comprise a mobile phase A and a mobile phase B, the mobile phase A is a monopotassium phosphate aqueous solution, the mobile phase B is methanol, and the 6-chloroindole-2-one related substances are detected. The method is good in specificity, high in sensitivity, high in accuracy and good in repeatability.